Last reviewed · How we verify

NCT05634031

Imaging Coronary Microvascular Dysfunction (CMD) Study

Recruiting now NA Last updated 16 April 2025
What this trial tests

NA trial testing PET imaging in Angina in 70 participants. Currently enrolling.

Timeline
26 April 2023
Primary endpoint
1 December 2026
1 March 2027

Quick facts

Lead sponsorIcahn School of Medicine at Mount Sinai
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment70
Start date26 April 2023
Primary completion1 December 2026
Estimated completion1 March 2027
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Icahn School of Medicine at Mount Sinai

Who can join

18 and older, any sex, with Angina or Non-obstructive Coronary Artery Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Angina is a common clinical symptom of ischemic heart disease, affecting up to 11 million people in the United States alone, and 112 million people globally. Despite this, 4 in 10 patients undergoing elective coronary angiography for angina and ischemia do not have evidence of obstructive coronary artery disease (CAD). This condition of ischemia with no obstructive CAD (INOCA) is associated with high clinical and economic morbidity, as these patients have a higher rate of repeat procedures and hospitalizations, worse quality of life, future adverse cardiovascular events and frequent time missed from work. The overall objective of this study is to develop and validate a non-invasive algorithm for diagnosis and management of patients with INOCA and suspected microvascular dysfunction centered around cardiac PET MPI. A secondary goal of the study is to assess for improvement in patient symptoms, function and quality of life from PET-guided management of CMD in patients with INOCA. This study will take place at Mount Sinai Morningside in the PET and CTunit on the 3rd floor. The sub-study will occur at Mount Sinai Morningside Cath Lab on the 3rd floor. The study will enroll an estimated total of 70 subjects, 12 of which will also participate in the sub-study. The study is estimated to last 2 years.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Neuro-immune interactions in coronary microvascular disease: mechanisms and therapeutic prospect.
    Ge Z, Wu G, Ma J, Ren S, et al · · 2025 · cited 1× · PMID 40948785 · DOI 10.3389/fimmu.2025.1631083

Verify or expand the search:

Other trials of PET imaging

Trials testing the same drug.

Other recruiting trials for Angina

Currently open trials in the same condition.

Other Icahn School of Medicine at Mount Sinai trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05634031.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing